These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11739186)

  • 1. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
    Demiroglu A; Steer EJ; Heath C; Taylor K; Bentley M; Allen SL; Koduru P; Brody JP; Hawson G; Rodwell R; Doody ML; Carnicero F; Reiter A; Goldman JM; Melo JV; Cross NC
    Blood; 2001 Dec; 98(13):3778-83. PubMed ID: 11739186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
    Fioretos T; Panagopoulos I; Lassen C; Swedin A; Billström R; Isaksson M; Strömbeck B; Olofsson T; Mitelman F; Johansson B
    Genes Chromosomes Cancer; 2001 Dec; 32(4):302-10. PubMed ID: 11746971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
    Tbakhi A; Pettay J; Sreenan JJ; Abdel-Razeq H; Kalaycio M; Hoeltge G; Miller ML; Tubbs RR
    Am J Clin Pathol; 1998 Jan; 109(1):16-23. PubMed ID: 9426513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p.
    Pini M; Gottardi E; Scaravaglio P; Giugliano E; Libener R; Baraldi A; Muzio A; Cornaglia E; Saglio G; Levis A
    Hematol J; 2002; 3(6):315-6. PubMed ID: 12522455
    [No Abstract]   [Full Text] [Related]  

  • 5. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
    Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
    Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.
    Roumiantsev S; Krause DS; Neumann CA; Dimitri CA; Asiedu F; Cross NC; Van Etten RA
    Cancer Cell; 2004 Mar; 5(3):287-98. PubMed ID: 15050920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
    Kulkarni S; Heath C; Parker S; Chase A; Iqbal S; Pocock CF; Kaeda J; Cwynarski K; Goldman JM; Cross NC
    Cancer Res; 2000 Jul; 60(13):3592-8. PubMed ID: 10910073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.
    Murati A; Arnoulet C; Lafage-Pochitaloff M; Adélaide J; Derré M; Slama B; Delaval B; Popovici C; Vey N; Xerri L; Mozziconacci MJ; Boulat O; Sainty D; Birnbaum D; Chaffanet M
    Int J Oncol; 2005 Jun; 26(6):1485-92. PubMed ID: 15870860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
    Chen J; Deangelo DJ; Kutok JL; Williams IR; Lee BH; Wadleigh M; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Galinsky I; Huntly B; Cohen PS; Meyer T; Fabbro D; Roesel J; Banerji L; Griffin JD; Xiao S; Fletcher JA; Stone RM; Gilliland DG
    Proc Natl Acad Sci U S A; 2004 Oct; 101(40):14479-84. PubMed ID: 15448205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of four new translocations involving FGFR1 in myeloid disorders.
    Sohal J; Chase A; Mould S; Corcoran M; Oscier D; Iqbal S; Parker S; Welborn J; Harris RI; Martinelli G; Montefusco V; Sinclair P; Wilkins BS; van den Berg H; Vanstraelen D; Goldman JM; Cross NC
    Genes Chromosomes Cancer; 2001 Oct; 32(2):155-63. PubMed ID: 11550283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome.
    Reiter A; Sohal J; Kulkarni S; Chase A; Macdonald DH; Aguiar RC; Gonçalves C; Hernandez JM; Jennings BA; Goldman JM; Cross NC
    Blood; 1998 Sep; 92(5):1735-42. PubMed ID: 9716603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.
    Heath C; Cross NC
    J Biol Chem; 2004 Feb; 279(8):6666-73. PubMed ID: 14660670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K; Weisberg E; Gilliland DG; Griffin JD
    Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.
    Cox MC; Maffei L; Buffolino S; Del Poeta G; Venditti A; Cantonetti M; Aronica G; Aquilina P; Masi M; Amadori S
    Am J Clin Pathol; 1998 Jan; 109(1):24-31. PubMed ID: 9426514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.
    Grand EK; Grand FH; Chase AJ; Ross FM; Corcoran MM; Oscier DG; Cross NC
    Genes Chromosomes Cancer; 2004 May; 40(1):78-83. PubMed ID: 15034873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.
    Xiao S; Nalabolu SR; Aster JC; Ma J; Abruzzo L; Jaffe ES; Stone R; Weissman SM; Hudson TJ; Fletcher JA
    Nat Genet; 1998 Jan; 18(1):84-7. PubMed ID: 9425908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.
    Safley AM; Sebastian S; Collins TS; Tirado CA; Stenzel TT; Gong JZ; Goodman BK
    Genes Chromosomes Cancer; 2004 May; 40(1):44-50. PubMed ID: 15034867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3).
    Guasch G; Popovici C; Mugneret F; Chaffanet M; Pontarotti P; Birnbaum D; Pébusque MJ
    Blood; 2003 Jan; 101(1):286-8. PubMed ID: 12393597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.